Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging host cell targets for hepatitis C therapy.

Yupeng He1, Wei Duan, Seng-Lai Tan

  • 1Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. yupeng.he@abbott.com

Drug Discovery Today
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TLR-induced STK25 activation promotes IRF5-mediated inflammation.

Life science alliance·2025
Same author

Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R.

Biomaterials·2024
Same author

Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R.

bioRxiv : the preprint server for biology·2023
Same author

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.

Cancer research·2023
Same author

A test-retest resting, and cognitive state EEG dataset during multiple subject-driven states.

Scientific data·2022
Same author

Symmetric subgenomes and balanced homoeolog expression stabilize the establishment of allopolyploidy in cyprinid fish.

BMC biology·2022

Chronic hepatitis C virus (HCV) infection requires new therapies due to limited efficacy of current treatments. Targeting host cell factors involved in HCV infection and replication offers promising therapeutic strategies.

Area of Science:

  • Virology
  • Hepatology
  • Drug Discovery

Background:

  • Chronic hepatitis C virus (HCV) infection poses a significant global health challenge.
  • Existing HCV therapies demonstrate limited efficacy, necessitating the development of novel treatment approaches.
  • Host cellular factors are critical for HCV infection, replication, and pathogenesis, presenting potential therapeutic targets.

Purpose of the Study:

  • To identify and evaluate host cell factors essential for HCV infection and replication.
  • To explore the potential of targeting these cellular factors for developing new anti-HCV therapies.
  • To investigate intracellular pathways, including lipid biosynthesis, oxidative stress, and innate immunity, in the context of HCV.

Main Methods:

  • Review of current literature on HCV pathogenesis and host-pathogen interactions.

Related Experiment Videos

  • Analysis of cellular receptors mediating HCV entry.
  • Investigation of factors facilitating HCV replication and assembly.
  • Examination of intracellular pathways affected by HCV infection.

    • Main Results:

    • Host cellular factors, including entry receptors and replication facilitators, are crucial for the HCV life cycle.
    • Intracellular pathways such as lipid biosynthesis, oxidative stress, and innate immune responses are implicated in HCV pathogenesis.
    • Pharmacological manipulation of these cellular targets is a key challenge for effective HCV treatment.

    Conclusions:

    • Host cell factors represent promising targets for novel chronic hepatitis C virus therapies.
    • Understanding HCV's reliance on host cell machinery is vital for therapeutic intervention.
    • Developing targeted therapies that minimize side effects remains a critical objective for HCV treatment.